<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002913</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02251</org_study_id>
    <secondary_id>GOG-9602</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <secondary_id>CDR0000065286</secondary_id>
    <nct_id>NCT00002913</nct_id>
  </id_info>
  <brief_title>Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer</brief_title>
  <official_title>PHASE I STUDY OF PACLITAXEL COMBINED WITH TOPOTECAN AND CISPLATIN AND G-CSF IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN EPITHELIAL MALIGNANCIES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of paclitaxel, cisplatin, and topotecan with or&#xD;
      without filgrastim in treating patients who have newly diagnosed stage III or stage IV&#xD;
      epithelial ovarian cancer. Drugs used in chemotherapy use different ways to stop tumor cells&#xD;
      from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may&#xD;
      increase the number of immune cells found in bone marrow or peripheral blood and may help a&#xD;
      person's immune system recover from the side effects of chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated doses of paclitaxel, cisplatin, and topotecan administered&#xD;
      together with or without filgrastim (G-CSF) in patients with newly diagnosed advanced ovarian&#xD;
      cancer.&#xD;
&#xD;
      II. Describe and quantitate the clinical toxic effects of combination chemotherapy with&#xD;
      paclitaxel, cisplatin, and topotecan with or without G-CSF.&#xD;
&#xD;
      III. Assess preliminary evidence of antitumor activity of this combination chemotherapy in&#xD;
      these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of topotecan.&#xD;
&#xD;
      Patients receive paclitaxel IV over 3 hours and cisplatin IV on day 1, followed by topotecan&#xD;
      IV over 30 minutes on days 1-3. Patients receive filgrastim (G-CSF) subcutaneously beginning&#xD;
      on day 4 and continuing until blood counts recover. Treatment repeats every 3 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 4-6 patients receive escalating doses of topotecan until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose limiting toxicities.&#xD;
&#xD;
      Patients are followed as clinically indicated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1996</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximally tolerated doses (MTDs) of the combination of paclitaxel, Topotecan, and cisplatin administered without and with G-CSF based on dose-limiting toxicities (DLT) graded according to GOG Common Toxicity Criteria</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Brenner Tumor</condition>
  <condition>Ovarian Clear Cell Cystadenocarcinoma</condition>
  <condition>Ovarian Endometrioid Adenocarcinoma</condition>
  <condition>Ovarian Mixed Epithelial Carcinoma</condition>
  <condition>Ovarian Mucinous Cystadenocarcinoma</condition>
  <condition>Ovarian Serous Cystadenocarcinoma</condition>
  <condition>Ovarian Undifferentiated Adenocarcinoma</condition>
  <condition>Stage III Ovarian Epithelial Cancer</condition>
  <condition>Stage IV Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (paclitaxel, cisplatin, topotecan hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 3 hours and cisplatin IV on day 1, followed by topotecan IV over 30 minutes on days 1-3. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until blood counts recover. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 4-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, cisplatin, topotecan hydrochloride)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, cisplatin, topotecan hydrochloride)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, cisplatin, topotecan hydrochloride)</arm_group_label>
    <other_name>hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>TOPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (paclitaxel, cisplatin, topotecan hydrochloride)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed epithelial ovarian carcinoma&#xD;
&#xD;
               -  No borderline ovarian carcinoma&#xD;
&#xD;
               -  Stage III/IV disease that has been suboptimally or optimally debulked&#xD;
&#xD;
          -  The following histologies are eligible:&#xD;
&#xD;
               -  Adenocarcinoma (unspecified)&#xD;
&#xD;
               -  Mucinous cystadenocarcinoma&#xD;
&#xD;
               -  Clear cell adenocarcinoma&#xD;
&#xD;
               -  Serous cystadenocarcinoma&#xD;
&#xD;
               -  Endometrioid adenocarcinoma&#xD;
&#xD;
               -  Transitional cell carcinoma&#xD;
&#xD;
               -  Malignant Brenner's tumor&#xD;
&#xD;
               -  Undifferentiated carcinoma&#xD;
&#xD;
               -  Mixed epithelial carcinoma&#xD;
&#xD;
               -  Extraovarian papillary serous cystadenocarcinoma&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Performance status - GOG 0-1&#xD;
&#xD;
          -  Enabling completion of at least 2 courses of therapy&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No myocardial infarction within 6 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No unstable or uncontrolled angina&#xD;
&#xD;
          -  No history of cardiac arrhythmia requiring anti-arrhythmia medication&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No hypersensitivity to E. coli-derived drug preparation&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No sensory neuropathy&#xD;
&#xD;
          -  No other malignancies within the past 5 years except nonmelanomatous skin cancer&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  Recovered from any recent surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Armstrong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Cystadenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Brenner Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

